Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
Sponsor: University of Michigan
Summary
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
Official title: Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs: an Interventional Study
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-09-02
Completion Date
2026-09
Last Updated
2025-09-15
Healthy Volunteers
Yes
Conditions
Interventions
Sotagliflozin (SOTA) followed by 3 drugs in a random order
400 mg/day SOTA Each drug will be given daily for 2 weeks.
Aspirin followed by 3 drugs in a random order
81 mg/day Aspirin Each drug will be given daily for 2 weeks.
Clopidogrel followed by 3 drugs in a random order
75 mg/day clopidogrel Each drug will be given daily for 2 weeks.
Eliquis followed by 3 drugs in a random order
5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.
Locations (1)
University of Michigan
Ann Arbor, Michigan, United States